Thermo Fisher Scientific Specialty Diagnostics — Cost of revenues increased by 2.1% to $682.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.1%, from $668.00M to $682.00M. This increase may warrant attention — for this metric, lower values are generally preferred.
A rising ratio relative to revenue suggests margin compression, while a falling ratio indicates improved manufacturing efficiency.
The direct costs attributable to the production and delivery of diagnostic products and services within the Specialty Di...
Standard metric for assessing gross margin health across the life sciences industry.
tmo_segment_specialty_diagnostics_cost_of_revenues| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|
| Value | $646.00M | $646.00M | $646.00M | $646.00M | $668.00M | $682.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +3.4% | +2.1% |
| YoY Change | — | — | — | — | +3.4% | +2.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.